Home › Trial NCT03234335
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment
- Trial IDNCT03234335
- StatusCompleted
- PhaseN/A
- Study typeObservational
- SponsorCentre Hospitalier Universitaire de Saint Etienne
- Enrollment50
- Start date2018-04-10
- ConditionsMultiple Myeloma · Renal Failure
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.